CureVac (NASDAQ:CVAC – Get Rating) was upgraded by inventory analysts at Jefferies Monetary Group from a “maintain” score to a “purchase” score in a analysis report issued on Friday, The Fly experiences.
Individually, JMP Securities dropped their worth goal on CureVac from $37.00 to $34.00 and set a “market outperform” score for the corporate in a analysis be aware on Thursday, November seventeenth.
CureVac Value Efficiency
Shares of CVAC stock opened at $8.26 on Friday. CureVac has a 12 month low of $5.63 and a 12 month excessive of $31.84. The corporate has a present ratio of three.61, a fast ratio of three.56 and a debt-to-equity ratio of 0.06. The inventory has a 50-day transferring common worth of $7.20 and a 200 day transferring common worth of $9.70.
Institutional Buying and selling of CureVac
A lot of hedge funds have lately purchased and bought shares of CVAC. JPMorgan Chase & Co. grew its stake in shares of CureVac by 35.8% within the first quarter. JPMorgan Chase & Co. now owns 22,817 shares of the corporate’s inventory price $448,000 after buying a further 6,016 shares over the last quarter. Financial institution of New York Mellon Corp elevated its holdings in shares of CureVac by 2.3% within the first quarter. Financial institution of New York Mellon Corp now owns 103,549 shares of the corporate’s inventory valued at $2,030,000 after buying a further 2,286 shares over the last quarter. Citigroup Inc. grew its stake in CureVac by 120.2% throughout the first quarter. Citigroup Inc. now owns 16,469 shares of the corporate’s inventory price $323,000 after shopping for a further 98,177 shares within the final quarter. Healthcare of Ontario Pension Plan Belief Fund purchased a brand new place in CureVac within the 1st quarter valued at roughly $549,000. Lastly, BlackRock Inc. raised its holdings in CureVac by 6.2% throughout the 1st quarter. BlackRock Inc. now owns 1,915,548 shares of the corporate’s inventory price $37,564,000 after buying a further 111,590 shares over the last quarter.
CureVac N.V., a clinical-stage biopharmaceutical firm, focuses on growing varied transformative medicines based mostly on messenger ribonucleic acid (mRNA). It’s growing prophylactic vaccines, akin to mRNA-based vaccine candidates CV2CoV, which is in Section 1 medical trial towards SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has accomplished Section 1 medical trial for rabies virus glycoprotein; and CVSQIV, which is in Section 1 medical trial towards influenza, in addition to vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and common influenza.
This prompt information alert was generated by narrative science know-how and monetary information from MarketBeat so as to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial crew previous to publication. Please ship any questions or feedback about this story to firstname.lastname@example.org.
Earlier than you take into account CureVac, you will need to hear this.
MarketBeat retains observe of Wall Road’s top-rated and finest performing analysis analysts and the shares they suggest to their shoppers every day. MarketBeat has recognized the five stocks that prime analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and CureVac wasn’t on the record.
Whereas CureVac at the moment has a “Maintain” score amongst analysts, top-rated analysts imagine these 5 shares are higher buys.